...
首页> 外文期刊>BMC Neurology >Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome
【24h】

Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome

机译:与多巴胺能疗法相关的冲动控制行为在不安腿综合征中的发生频率

获取原文
           

摘要

Background Low doses of dopamine agonists (DA) and levodopa are effective in the treatment of restless legs syndrome (RLS). A range of impulse control and compulsive behaviours (ICBs) have been reported following the use of DAs and levodopa in patients with Parkinson's disease. With this study we sought to assess the cross-sectional prevalence of impulse control behaviours (ICBs) in restless legs syndrome (RLS) and to determine factors associated with ICBs in a population cohort in Germany. Methods Several questionnaires based on validated and previously used instruments for assessment of ICBs were mailed out to patients being treated for RLS. Final diagnoses of ICBs were based on stringent diagnostic criteria after psychiatric interviews were performed. Results 10/140 RLS patients of a clinical cohort (7.1%) were finally diagnosed with ICBs, 8 of 10 on dopamine agonist (DA) therapy, 2 of 10 on levodopa. 8 of the 10 affected patients showed more than one type of abnormal behaviour. Among those who responded to the questionnaires 6/140 [4.3%] revealed binge eating, 5/140 [3.6%] compulsive shopping, 3/140 [2.1%] pathological gambling, 3/140 [2.1%] punding, and 2/140 [1.4%] hypersexuality in psychiatric assessments. Among those who did not respond to questionnaires, 32 were randomly selected and interviewed: only 1 patient showed positive criteria of ICBs with compulsive shopping and binge eating. ICBs were associated with higher DA dose (p = 0.001), younger RLS onset (p = 0.04), history of experimental drug use (p = 0.002), female gender (p = 0.04) and a family history of gambling disorders (p = 0.02), which accounted for 52% of the risk variance. Conclusion RLS patients treated with dopaminergic agents and dopamine agonists in particular, should be forewarned of potential side effects. A careful history of risk factors should be taken.
机译:背景低剂量的多巴胺激动剂(DA)和左旋多巴可有效治疗腿不安综合症(RLS)。在帕金森氏病患者中使用DA和左旋多巴后,已经报道了一系列冲动控制和强迫行为(ICB)。通过这项研究,我们试图评估躁动性腿综合征(RLS)中冲动控制行为(ICB)的横断面患病率,并确定与德国某人群中ICB相关的因素。方法将几份基于经过验证的和先前使用的用于评估ICB的工具的问卷邮寄给接受RLS治疗的患者。对ICB的最终诊断是基于进行精神病学访谈后的严格诊断标准。结果10/140例临床队列的RLS患者(7.1%)最终被诊断出患有ICB,多巴胺受体激动剂(DA)治疗10人中有8人,左旋多巴10人中有2人。 10名受影响的患者中有8名表现出一种以上的异常行为。在接受问卷调查的受访者中,有6/140 [4.3%]发现暴饮暴食,5/140 [3.6%]强迫性购物,3/140 [2.1%]病理性赌博,3/140 [2.1%]暴打和2 /在精神病学评估中有140 [1.4%]性欲亢进。在不回答问卷的人中,随机选择32名并进行了访谈:只有1名患者表现出强迫性购物和暴饮暴食的ICB阳性标准。 ICB与更高的DA剂量(p = 0.001),更年轻的RLS发作(p = 0.04),实验用药史(p = 0.002),女性(p = 0.04)和赌博疾病家族史(p = 0.02),占风险差异的52%。结论应特别警告使用多巴胺能药物和多巴胺激动剂治疗的RLS患者潜在的副作用。应仔细考虑危险因素的病史。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号